A66 NEW

Price	$46	$76	$147
Package	5mg	10mg	25mg

Min. Order:
Supply Ability:	10g
Update Time:	2024-11-19

Product Details

Product Name: A66	CAS No.: 1166227-08-2
Purity: ≥95%	Supply Ability: 10g
Release date: 2024/11/19

Product Introduction

Bioactivity

Name	A66
Description	A66 is a specific and effective p110α inhibitor(IC50=32 nM).
Kinase Assay	IC50 values are evaluated using the PI3K (human) HTRF Assay. p85α/p110δ is obtained from Invitrogen. All other isoforms are produced in-house by co-expressing full-length human p85α with the indicated human full-length catalytic subunit containing a histidine tag at the N-terminus to allow purification. The PI3Ks are titrated and used at a concentration between their EC65-EC80 values. PI3K activity in immunoprecipitates is assayed using an antibody to the N-SH2 (N-Src homology 2) domain of p85α. Assays for other lipid kinases and protein kinases are performed by the National Centre for Protein Kinase Profiling and Invitrogen Drug Discovery Services[1].
In vitro	In male CD1 mice, A66 (10 mg/kg) increased glucose production during the pyruvate tolerance test. In SK-OV-3 tumor tissues, A66 (100 mg/kg) effectively reduced the phosphorylation of Akt/PKB and p70 S6 kinase, inhibiting tumor cell growth.
In vivo	A66 significantly inhibits the oncogenic forms of p110α, such as p110αE545K (IC50=30 nM) and p110αH1047R (IC50=43 nM), effectively reducing their activity.
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : 1 mg/mL (2.54 mM) DMSO : 60 mg/mL (152.47 mM), Sonication is recommended.
Keywords	Phosphoinositide 3-kinase \| inhibit \| PI3K \| Inhibitor \| A66 \| A-66 \| A 66
Inhibitors Related	Myricetin \| Erucic acid \| Sapanisertib \| (2S,3R,4S)-4-Hydroxyisoleucine \| Duvelisib (R enantiomer) hydrochloride \| Isoprenaline hydrochloride \| Quercetin \| GDC0084 \| Quercetin Dihydrate \| Apilimod \| LY294002 \| Idelalisib
Related Compound Libraries	Highly Selective Inhibitor Library \| Anti-Lung Cancer Compound Library \| Bioactive Compound Library \| Antidepressant Compound Library \| Kinase Inhibitor Library \| Inhibitor Library \| Anti-Aging Compound Library \| Bioactive Compounds Library Max \| Neuronal Differentiation Compound Library \| Oxidation-Reduction Compound Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.